- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03574181
Calibration Study of a Blood Alcohol Level Smart Watch
Calibration Study of a Wearable Noninvasive Blood Alcohol Monitor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this proposed study, the objective is to further demonstrate the reliability of this printed electrochemical gas sensor in the form of a wearable device. This demonstration of reliability among human subjects is an essential part of product development. The monitor will be in a wristband or watch form, similar to a smart watch. This device will be modern, attractive and comfortable. It will also have smart watch features including measuring key physiological parameters (e.g., pulse) and eventually will have connectivity to apps on smart phones and other devices. The aim of the work is to provide a new, noninvasive transdermal alcohol monitor into the market. The transdermal alcohol monitoring market has few wearable products available and innovation has been lacking in this field. This new product will take advantage of current trends in wearable technology. As the public becomes more comfortable with wearable sensors, the blood alcohol monitor will become popular with people interested in health and fitness who want to track their alcohol intake. The product will provide a new, highly reliable and sensitive method for tracking blood alcohol level. This may be particularly beneficial to individuals who seek to reduce the risk of alcohol use by limiting peak blood alcohol level. If successful, this technology could be adopted in many areas including clinical and medical treatment, employee wellness programs, alcohol clinical trials, and as part of brief interventions that target at-risk drinkers.
The specific objective of this study is to determine whether the printed electrochemical gas sensor designed to measure blood alcohol level will be sensitive and reliable when compared to a standard measure of blood alcohol level taken by a breathalyzer. If this sensor proves sensitive to changes in blood alcohol level and can reliably measure blood alcohol level relative to a "gold standard" method, there are significant opportunities to use this technology in consumer health applications and clinical research.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston University Psychiatry Research Center, Clinical Studies Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 21-55 years of age.
- Can provide proof of age with state or federal picture Identification.
- Consumes an average of ≥7 standard drinks per week (women) or ≥14 drinks per week (men) over the 28 days prior to consent.
- Has consumed at least 4 standard drinks on a single day on at least two days in the past 28 days prior to consent.
- Has a blood alcohol level = 0.000 at time of consent.
- Is able to understand and provide written informed consent.
- Body weight ≥ 120 lbs and ≤ 250 pounds
- Subjects can speak and understand English
Exclusion Criteria:
- Currently seeking treatment for alcohol problems or purposefully abstaining from alcohol in an attempt to cut back or quit drinking.
- Clinical Institute Withdrawal Assessment at ≥10.
- Meets DSM-5 diagnosis of current major depression, bipolar disorder, schizophrenia, bulimia/anorexia, dementia, or a substance use disorder other than alcohol, nicotine, marijuana, or caffeine
- If female, pregnant or nursing.
- If female, does not agree to use an accepted form of birth control
- Has medical or mental condition for which further alcohol exposure at the planned dose range would be contraindicated.
- Taking medication for which drinking would be contraindicated.
- Clinically significant abnormal ECG.
- AST or ALT ≥ 3x the upper limit of normal.
- Current risk of suicidality.
- Has taken medications that are used to treat AUD in the past 90 days.
- Has received alcohol counseling or other non-pharmacologic intervention to treat alcohol use disorder in the past 90 days.
- Has urine toxicology results positive for cocaine, opioids, amphetamines, buprenorphine, methadone, or methamphetamines.
- Smokes greater than 5 cigarettes per day.
- Unable to comfortably abstain from nicotine for a period of 8 hours.
- Wearing cologne, perfume, aftershave or any other scented oil or alcohol-based beauty product on the day of the Alcohol Lab Visit.
- Has dietary restrictions that would preclude participating.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation Between Breathalyzer and Wristwatch Sensor BAL Measurements
Time Frame: 6 hours during alcohol self administration trial
|
Wristwatch sensor BAL is continuously measured for entirety of 6-hour alcohol self administration trial.
BAL from breathalyzer (BrAC) is measured at 15-minute intervals throughout 6-hour alcohol self administration trial.
The correlation between wristwatch transdermal BAL (TAC) and breathalyzer BAL (BrAC) for all subjects will be calculated.
|
6 hours during alcohol self administration trial
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric Devine, PhD, Boston Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-36914
- R44AA024651-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Drinking
-
University of North Carolina, Chapel HillNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingDrinking Behavior | Adolescent Behavior | Drinking, Alcohol | Alcohol Drinking, AdolescentUnited States
-
Boston University Charles River CampusRecruiting
-
University of Auckland, New ZealandTe Hiringa Hauora/Health Promotion AgencyCompletedDrinking, Alcohol | Consumption, AlcoholNew Zealand
-
University of ArkansasRecruitingDrinking Behavior | Drinking Excessive | DrinkingUnited States
-
Butler HospitalNational Institute of General Medical Sciences (NIGMS)CompletedDrinking, AlcoholUnited States
-
Real Prevention, LLCCompletedUnderage Drinking | Alcohol Use, UnderageUnited States
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Active, not recruiting
-
University of North Texas Health Science CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Universidad de GranadaCompletedExercise | Drinking, AlcoholSpain
-
Lehigh UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Brown UniversityCompletedCollege DrinkingUnited States
Clinical Trials on Smartwatch to measure Blood Alcohol Level (BAL)
-
University of FloridaWithdrawnAortic Stenosis | Transcatheter Aortic Valve Replacement | Glutathione Peroxidase ActivityUnited States
-
Centre Hospitalier Universitaire de Saint EtienneInstitut de Cancérologie de la Loire; Laboratoire Interuniversitaire de Biologie...TerminatedMyelodysplatic SyndromesFrance
-
Hospital Universitario GetafeCompletedCorrelation Between Exhaled Carbon Dioxide and in Arterial BloodSpain
-
Hadassah Medical OrganizationRecruiting
-
Yale UniversityNatera, Inc.; Yale Cardiovascular Research GroupSuspendedEndothelial Dysfunction | Microvascular Coronary Artery Disease | Cardiac Allograft VasculopathyUnited States
-
Centre Hospitalier Universitaire, AmiensCompletedPneumonia | AntibioticsFrance
-
University Hospital, GrenobleUnknown
-
Hospices Civils de LyonCompleted
-
National Taiwan University HospitalRecruiting
-
University of MinnesotaRecruitingHypertension | Menopause | Blood Pressure | Menopause, PrematureUnited States